17 results about "AIM antigen" patented technology

Embodiments of the present disclosure disclose an antigen-antibody binding conformation optimization method and device based on iterative closest point. A specific embodiment of the method comprises: obtaining a coarse-grained antibody file and a coarse-grained antigen file; performing surface residue extraction on the antigen structure file and the antibody structure file to obtain an antigen surface residue information set and an antibody surface residue information set; generating an antibody binding region residue list; generating an epitope model; performing spatial matching on the antigen surface residue information set and the epitope model to obtain a matched epitope model; generating an antibody docking conformation set; performing local optimization on each antibody docking conformation in the antibody docking conformation set to obtain an optimized antibody conformation set; and screening each optimized antibody conformation in the optimized antibody conformation set to obtain a target antigen-antibody binding conformation. The embodiment can improve the accuracy of the antibody conformation.

The invention provides a double-antibody directionally-coupled FET (Field Effect Transistor) biosensor and a preparation method thereof, and belongs to the technical field of biosensors. The FET biosensor adopts a reference electrode to provide grid voltage, a buffer solution is a conductive electrolyte, the FET biosensor comprises a field effect transistor, a capture antibody and a detection antibody, the field effect transistor is composed of a source electrode, a drain electrode and a channel between the source electrode and the drain electrode, the bottom layer of the channel is an indium oxide thin film layer, the indium oxide thin film layer is modified with amino, and the detection antibody is a detection antibody. An amino-modified channel is obtained; carrying out passivation treatment on the source electrode and the drain electrode by adopting a mercaptan passivator; and cross-linking and fixing the capture antibody and the detection antibody on the channel modified with the amino group through a cross-linking fixing agent to obtain the FET biosensor. The two antibodies are combined according to different epitopes of antigens to form a sandwich structure, and double recognition of the antibodies on target antigens is utilized to enhance antigen capture efficiency and signal enrichment, so that a double-site recognition mode is formed, and low-concentration antigen detection is realized.

This disclosure provides an immunoassay with exceptional sensitivity for detecting a target antigen in a sample. In one disclosure, the capture and detection steps of such an assay utilize recombinant antibodies. The disclosed immunoassay may find specific applications in the detection of HBV antigen.

The purpose of the present invention is to provide, as a platform technique that may serve as preparation for pandemics, a rapid antibody production technique in which a non-human animal having a human antibody gene is used. More specifically, the purpose of the present invention is to provide an immunization method with which it is possible to induce, in a short period of time, a high antigen-binding ability of an antibody or a high antibody titer of an antiserum, and a method for producing a human antibody / antiserum with which it is possible to rapidly produce a wide range of neutralizing antibodies.　(1) An immunization method for rapidly inducing a human monoclonal antibody having a high ability to bind to a desired antigen or a human polyclonal antibody having a high antibody titer, the method comprising a step for immunizing a non-human animal a plurality of times with a desired antigen or a nucleic acid encoding the antigen within 30 days from the first immunization, the non-human animal having a human antibody gene or locus, and the non-human animal being such that an endogenous gene or locus of the non-human animal corresponding to the human antibody gene or locus is disrupted or deleted, or mutated so as to result in a loss of expression or low expression. (2) A method for producing a human antibody against a desired antigen using a non-human animal, the method comprising: an immunization step for immunizing the non-human animal with the antigen or a nucleic acid encoding the antigen; a human immunoglobulin-positive B cell isolation step for isolating B cells that are human immunoglobulin-positive from a tissue of the immunized non-human animal; an antibody base sequence acquisition step for acquiring the base sequences of antibody light-chain mRNA-derived cDNA and antibody heavy-chain mRNA-derived cDNA prepared from the isolated B cells; and an antibody production step for producing an antibody on the basis of the acquired antibody base sequence, the non-h

Provided herein are lipidated imidazoquinoline compounds and compositions comprising such compounds. The lipidated imidazoquinoline compounds may be used as an adjuvant to enhance to immune response elicited by an antigen of interest. Accordingly, also provided herein are methods for enhancing the immune response of an antigen of interest in a subject, comprising administering to the subject an antigen of interest with a lipidated imidazoquinoline compound described herein in an immunogenic composition, or administering to the subject a composition comprising a lipidated imidazoquinoline compound described herein in combination with (e.g., prior to, concurrently, or subsequently) the administration of an immunogenic composition comprising an antigen of interest to the subject.

The application discloses a digoxin nanobody and a preparation method and application thereof. The amino acid and nucleotide sequences of the digoxin nanobody are shown in SEQ ID NO. 8-9. The antibody has good affinity to a target antigen, and the dissociation constant Kd value is about 73.1 nM, and can be used for digoxin content determination, nucleic acid probe detection and in-vivo digoxin neutralization and detoxification. The antibody has the advantages of small volume, high stability, low cost, low immunogenicity and the like, and has a good application prospect.

Disclosed herein is a universal species-independent method for characterizing antibodies present in a sample that may provide protective immunity against a given pathogen or antigen of interest.

The application discloses a universal DC and a preparation method and application thereof, and belongs to the technical field of immune cells. The universal DC is obtained by knocking out HLA-I class genes in original DCs, and does not express HLA-I class molecules. In application, according to HLA-I class molecule typing of target antigen-specific T cells to be obtained, HLA-I class molecules matched with the target antigen-specific T cells are re-expressed in the universal DCs through gene editing, virus or mRNA technology, so that the limitation of HLA-I class molecule cell-specific matching of allogeneic DCs in application is overcome, and the problem of insufficient coverage of single DC HLA-I class molecule typing is solved.

The invention relates to the technical field of antibodies, and discloses an antibody for specifically recognizing porcine pseudorabies virus gE (52-260aa) or an antigen binding fragment thereof and application. The antibody or the antigen binding fragment thereof comprises a heavy chain and a light chain; the antibody can realize specific recognition on gE protein and is used for detecting a target antigen in a sample. The antibody can be used as a core reagent in an immunodetection system, is suitable for laboratory detection and on-site rapid screening of porcine pseudorabies, is beneficial to improving the monitoring efficiency of basic-level and large-scale breeding links, and provides a technical guarantee for early discovery and accurate prevention and control of epidemic situations. Meanwhile, the antibody can also be used as a research tool to be applied to research on gE protein related biological functions and effects of the gE protein in a virus pathopoiesis process, and important support is provided for clarification of virus variation characteristics and optimization of subsequent prevention and control and diagnosis strategies.

The invention discloses an LSPR (Local Surface Plasmon Resonance) micro-fluidic chip system for rapid typing detection of various virus antigens, and particularly relates to the cross technical field of biomedical engineering, a micro-nano sensing technology, molecular diagnosis and micro-fluidic chip application. According to the present invention, by introducing the PEGylation anti-fouling layer and the BSA sealing treatment, the non-specific adsorption interference is effectively reduced, and compared with the problems that the traditional antigen rapid detection (Ag-RDT) is easily influenced by the virus epitope mutation and the variation is difficult to distinguish, the system can utilize the LSPR peak position red shift difference caused by the combination of different variation antigens and the specific antibody to achieve the precise typing of the multi-variant virus, meanwhile, white light dark field hyperspectral detection is combined with baseline correction, noise filtering and other algorithms, spectral signals can be accurately extracted, and even if interference components such as impurity protein and cell debris exist in a sample, feature signals of a target antigen can still be stably recognized.

The invention discloses an immunodetection probe, a kit and a detection method based on proximity ligation and nucleic acid amplification in the technical field of biological detection. The immunodetection probe comprises an antibody modified probe A, an antibody modified probe B and a splint probe, the antibody modification probe A comprises a first antibody and a first DNA chain, the antibody modification probe B comprises a second antibody and a second DNA chain, and the splint probe sequentially comprises a front end chain, a primer complementary chain and a rear end chain from the 5'end to the 3 'end; the first antibody and the second antibody can be specifically combined with different epitopes of the same target antigen to form a sandwich compound. By designing a double-hairpin closed probe with a synergistic effect, non-specific hybridization and connection are greatly inhibited from a molecular stress level by utilizing self-closing of a hairpin structure of the probe in an uncombined state and a specific open-loop mechanism under adjacent triggering, so that a background signal is remarkably reduced; the near-quantitative and high-efficiency formation of the circular DNA template is realized, and the uniformity and stability of signal generation are guaranteed.

This invention relates to the field of biomedical technology, specifically disclosing a biomimetic bacterial DNA nanomicelle, its preparation method, and its applications. By mimicking the structural and functional characteristics formed when microorganisms infect a host, exogenous nucleic acid stimulation signals and oxidative stress regulation functions are integrated into a single nanostructure. A micellar nanostructure is designed, comprising a complex of oligonucleotides containing CpG motifs and ferrocene groups, which is formed through self-assembly in solution. This nanomicelle can significantly promote the proliferation or differentiation of dendritic cells, improve their maturity, and enhance their immune activation capacity; by enhancing the cross-presentation capacity of dendritic cells to target antigens, it effectively promotes cytotoxic CD8+. + T-cell immune responses; it can also enhance the body's cellular immune response by inducing the activation and proliferation of antigen-specific cells. These DNA nanomicelles have significant clinical application value in areas such as vaccine adjuvants, tumor immunotherapy, and immune regulation.

The present invention provides a novel CAR design containing a modified CD3ζ chain, and cells containing genetically modified immune-responsive cells (e.g., T cells, NK cells, or CTL cells) containing the CAR. [Solution] This disclosure provides a chimeric antigen receptor (CAR) that binds to an antigen of interest. The CAR can bind to a tumor antigen or a pathogen antigen. In certain non-limiting embodiments, the CAR comprises an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide.

Disclosed herein are binding polypeptides that bind to asialoglycoprotein receptor 1 (ASGR1), and methods of use thereof for inducing immune tolerance against antigens of interest, for example, for treating, ameliorating, inhibiting, or preventing disease or disorders associated with unwanted immune response against the antigens of interest, such as autoimmune diseases.

The invention discloses a novel immunodetection method and application. The immunodetection method comprises the following steps: coating a captured antibody and a single-site recognition antigen on a solid-phase carrier; adding a to-be-detected sample and a biotin-labeled mixed detection antibody for incubation, so that the target antigen forms a double-antibody sandwich compound, and the single-site recognition antigen and the detection antibody form a competitive compound; after streptavidin marked by chemiluminescence is added for incubation, signal values of the two compounds are detected; whether interference exists or not is judged and detected by comparing the double signals, and the content of the target antigen is determined. The immunodetection method can effectively identify cross interference and hook effect, and improves the accuracy and reliability of multi-index detection.

The application provides a computer-implemented method and device for tumor treatment strategy prediction, and belongs to the technical field of biological medicine. The method comprises the following steps: obtaining the proportion of target antigen-positive immune cells in total immune cells in a target sample; based on the difference between the proportion and a predetermined threshold, dividing the antigen expression level of the target sample to obtain a grouping result; wherein the grouping result is any one of N preset level groupings, and N is an integer not less than 1; based on the grouping result, matching a corresponding treatment strategy, wherein the treatment strategy comprises: administering an effective dose of an antibody corresponding to the target antigen and / or an immune checkpoint inhibitor antibody. By constructing a multi-level hierarchical mechanism based on the expression proportion of immune-related antigens and establishing a mapping relationship between the hierarchical result and the treatment strategy, fine immunotyping of tumor patients and individualized treatment strategy prediction are realized, so that the accuracy, safety and medical resource utilization rate of immunotherapy are improved.

According to the preparation method, the SERS substrate material with a highly ordered arrangement structure is prepared by taking gold nanorods as a core construction unit and adopting a phase transfer induced self-assembly strategy; a high-sensitivity SERS (Surface Enhanced Raman Scattering) analysis chip aiming at a nervous system injury marker GFAP (Glial Fibroblast Acid Protein) is constructed by further capturing an antibody through immobilized GFAP (Glial Fibroblast Acid Protein), an SERS probe with good immune recognition specificity is designed and prepared, and the SERS probe can be specifically combined with a target antigen. Based on the SERS platform, rapid, accurate and quantitative detection of the GFAP biomarker in the whole blood biological sample is realized, and the average detection time is only 5 minutes.